sperm autoantigenic protein 17Genealiases: CT22 · SP17 · SP17-1
Q-omics provides the consensus-scored SPA17 profile across patient tissues and cancer cell-line models. SPA17 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SPA17 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, SPA17 RNA expression shows 18,529 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, and UVM as cancer lineages where SPA17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPA17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPA17 survival associations across molecular data types. SPA17 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPA17 RNA expression–survival associations across cancer types. High SPA17 expression shows unfavorable associations in KICH, LIHC and LGG, but favorable associations in KIRC, UCEC and KIRP. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SPA17 RNA expression.
This table summarizes SPA17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SPA17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPA17 shows lower tumor expression in KICH, THCA, LUSC and LUAD and higher tumor expression in LIHC and STAD. The KICH box plot shows higher SPA17 RNA expression in normal versus tumor tissue (log2 FC = −2.564, t-test p < 0.001).
This table shows molecular features associated with SPA17 in patient tissues and cancer cell lines. In patient samples, SPA17 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPA17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
